Hydroquinone two-year dermal toxicity mouse study suggested at OTC "feedback" meeting.
This article was originally published in The Tan Sheet
Executive Summary
HYDROQUINONE TWO-YEAR DERMAL TOXICITY MOUSE STUDY SUGGESTED by FDA Division of OTC Drug Products Medical Officer Arther Baker, MD, at a Dec. 4 OTC "feedback" meeting on the ingredient between the agency, the Nonprescription Drug Manufacturers Association, Eastman Kodak and other industry members. Baker recommended that industry conduct a "two-year dermal toxicity exposure at a maximum tolerated dose, which is probably about 5%" hydroquinone in a specific mouse strain.